Lymphangiogenesis-related gene signature–based risk model for prognostic assessment of cervical cancer: immune–metabolic characterization and molecular subtype analysis
Aug 2026· Frontiers in Genetics· Vol 17· 0 citations· 44 references
Medicine
TL;DR
A lymphangiogenesis-related six-gene model enables clinically meaningful prognostic stratification of CESC and links lymphangiogenesis programs to distinct tumor immune phenotypes and therapeutic vulnerabilities.
Abstract
Background Lymphangiogenesis promotes tumor dissemination and may shape the immune contexture of cervical cancer, yet lymphangiogenesis-related prognostic stratification and its immunometabolic implications remain insufficiently defined in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). Methods TCGA-CESC transcriptomes and clinical data were obtained from UCSC Xena and integrated with normal cervix tissues from the Genotype-Tissue Expression Project after batch correction. Prognostic LYMRGs were first identified from the differentially expressed set using univariable Cox proportional hazards analysis. Candidate genes were then reduced using an L1-regularized Cox model (Least Absolute Shrinkage and Selection Operator), and the remaining markers were entered into a multivariable Cox regression to obtain the final coefficients and compute an individualized risk score. The model’s prognostic value was further assessed in an independent Gene Expression Omnibus dataset. In addition, expression patterns of the signature genes were leveraged for molecular subtyping of TCGA samples via non-negative matrix factorization (NMF). Immune infiltration and immunotherapy-associated characteristics were interrogated through a multi-algorithm strategy (single-sample gene set enrichment analysis, CIBERSORT, ESTIMATE, Tumor Immune Dysfunction and Exclusion (TIDE), and Immunophenoscore . Additional analyses included pathway enrichment (GSEA/GO/KEGG), drug sensitivity prediction (pRRophetic/CellMiner), and ceRNA network analysis. Results A six-gene LYMRG signature robustly stratified survival. High-risk patients had significantly worse overall survival in The Cancer Genome Atlas with AUCs of 0.819/0.801/0.801 at 1/3/5 years, and in GSE52903 (P = 0.001) with AUCs of 0.733/0.719/0.725. NMF identified two subtypes with distinct prognosis (P = 0.01) and divergent immune landscapes. Risk groups and subtypes exhibited consistent differences in immune infiltration, checkpoint expression, TIDE/IPS patterns, and pathway enrichment. Predicted chemosensitivity differed by risk group, and the ceRNA network suggested candidate upstream lncRNA regulators of the signature. Conclusion A lymphangiogenesis-related six-gene model enables clinically meaningful prognostic stratification of CESC and links lymphangiogenesis programs to distinct tumor immune phenotypes and therapeutic vulnerabilities.
A seven-gene immune-related prognostic signature that, combined with clinicopathological parameters, provides a robust tool for individualized survival prediction and may guide precision management in CRC patients is developed and validated.
This study proposes NET-related CRC molecular subtypes with oxidative stress-associated biological context and develops a transcriptomic risk model with external validation that suggests subtype-specific immune and therapeutic features, while prospective clinical and functional validation is required before clinical tr...
Yi Wei, Weijian Chu, Chunhui Rao et al.· Medicine· 0 citations
The results validate the biological significance of the model, highlight potential associations between lipid metabolism and the immune microenvironment in HNSCC, and provide a theoretical basis for further investigating metabolism-related therapeutic strategies.
Ting-Zhi Xie, Xin-Yi Sun, Jing Wang et al.· Oral Diseases· 0 citations
Investigation of MS-related prognostic genes and their potential biological relevance in CRC progression finds potential clues for future studies of CRC prognosis and MS-related tumor biology.
Breast cancer is highly heterogeneous, and immune–metabolic interactions within the tumor microenvironment may contribute to differences in clinical outcome. In this study, transcriptomic, clinical, and somatic mutation data from TCGA-BRCA were analyzed, and the prognostic model was evaluated in GSE199633, a retrospe...
Yu-Chen Li, Shao-Chao Zhan, Ting Li et al.· Scientific Reports· 0 citations
These findings identify a hypothesis-generating five-gene bulk-tissue prognostic signature and an expression-associated TFPI-high myofibroblast state but do not establish a discrete lineage, the cellular source of bulk TFPI, a TFPI-dependent mechanism, or clinical utility.
Yu Huang, Xian-Min Wu, Xiang-Nan Li et al.· Biomolecules & biomedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.